Previous Venous RCPs
Topic: Submassive Pulmonary Embolism Short and Long-term Outcomes: Where are We and Where Do We Need to Be
Lead investigator: Akhilesh Sista, MD, FSIR, Weill Cornell Medical College, N.Y.
Date: December 2015
After the RCP, Dr. Sista submitted a grant to the National Heart, Lung, and Blood Institute (NHLBI).
Topic: Critical issues in chronic central venous access and pathways for investigation
Lead investigator: Kevin Baskin, MD, Advanced Interventional Institute, Cranberry Township, Pa.
Date: October 2014
After the RCP, Dr. Baskin led the Venous Access: National Guideline and Registry Development (VANGUARD) Symposium at the National Institutes of Health from May 12-13, 2016. The SIR Foundation organized and supported the meeting to gather multiple stakeholders for discussion of future venous access research efforts, such as vocabulary development and registry design.
Topic: Interventional Endovascular Management of Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Lead investigators: Ziv Haskal, MD, FSIR, FAHA, FACR, FCIRSE, Editor, Journal of Vascular & Interventional Radiology, University of Maryland Medical Center, Baltimore, Md.;
Gary Siskin, MD, FSIR, Professor and Chairman, Department of Radiology, Albany Medical College, Albany, N.Y.
Date: October 2010
After the RCP, Dr. Haskal and Dr. Siskin were awarded the Funding Source Development Grant from SIR Foundation.
Topic: Inferior Vena Cava (IVC) Filters
Lead investigator: John Kaufman, MD, FSIR, Dotter Interventional Institute, Portland, Ore.
Date: June 2007
Topic: Venous Interventions
Lead investigator: Suresh Vendantham, MD, FSIR, Mallinckrodt Institute of Radiology, St. Louis, Mo.
Date: October 2004
After the RCP, Dr. Vendantham was awarded an R01 grant from the National Institutes of Health (NIH). The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-directed Thrombolysis (ATTRACT) trial was designed to evaluate the ability of catheter-directed thrombolysis to reduce the incidence and severity in patients with acute proximal deep vein thrombosis (DVT). ATTRACT received $10.2 million in funding, and has completed accrual of its originally planned cohort of 692 patients.